INCY
USDIncyte Corp. Common Stock
实时价格
价格图表
关键指标
市场指标
开盘价
$101.360
最高价
$103.860
最低价
$100.020
成交量
2.74M
公司基本面
市值
20.2B
所属行业
生物技术
国家/地区
United States
交易统计
平均成交量
2.00M
交易所
NMS
货币
USD
52周价格范围
相关新闻
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated
Incyte to Present at Upcoming Investor Conferences
Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84
RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.
